Immunomodulatory Strategies for Parapoxvirus: Current Status and Future Approaches for the Development of Vaccines against Orf Virus Infection
Authors:
- Alhaji Modu BukarAlhaji Modu Bukar
- Faez Firdaus Abdullah JesseFJFaez Firdaus Abdullah Jesse
- Che Azurahanim Che AbdullahCAChe Azurahanim Che Abdullah
- Mustapha M. NoordinMNMustapha M. Noordin
- Zaharaddeen LawanZLZaharaddeen Lawan
- Hassana Kyari ManggaHMHassana Kyari Mangga
- Krishnan Nair BalakrishnanKBKrishnan Nair Balakrishnan
- Mohd-Lila Mohd AzmiMAMohd-Lila Mohd Azmi
Open Access
Abstract
Orf virus (ORFV), the prototype species of the parapoxvirus genus, is the causative agent of contagious ecthyma, an extremely devastating skin disease of sheep, goats, and humans that causes enormous economic losses in livestock production. ORFV is known for its ability to repeatedly infect both previously infected and vaccinated sheep due to several immunomodulatory genes encoded by the virus that temporarily suppress host immunity. Therefore, the development of novel, safe and effective vaccines against ORFV infection is an important priority. Although, the commercially licensed live-attenuated vaccines have provided partial protection against ORFV infections, the attenuated viruses have been associated with major safety concerns. In addition to safety issues, the persistent reinfection of vaccinated animals warrants the need to investigate several factors that may affect vaccine efficacy. Perhaps, the reason for the failure of the vaccine is due to the long-term adaptation of the virus in tissue culture. In recent years, the development of vaccines against ORFV infection has achieved great success due to technological advances in recombinant DNA technologies, which have opened a pathway for the development of vaccine candidates that elicit robust immunity. In this review, we present current knowledge on immune responses elicited by ORFV, with particular attention to the effects of the viral immunomodulators on the host immune system. We also discuss the implications of strain variation for the development of rational vaccines. Finally, the review will also aim to demonstrate future strategies for the development of safe and efficient vaccines against ORFV infections.Keywords
Funding Information
- Skim Geran Penyelidikan Fundamental (FRGS) FASA 1/2019 University Putra Malaysia (FRGS/1/2019/STG03/UPM/01/2)
This publication has 170 references indexed in Scilit:
- Selective apoptosis induction in MCF-7 cell line by truncated minimal functional region of ApoptinBMC Cancer, 2013
- Vaccine delivery using nanoparticlesFrontiers in Cellular and Infection Microbiology, 2013
- Therapeutic immunomodulation using a virus—the potential of inactivated orf virusEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- Novel immune-modulator identified by a rapid, functional screen of the parapoxvirus ovis (Orf virus) genomeProteome Science, 2012
- A review of vaccine development and research for industry animals in KoreaClinical and Experimental Vaccine Research, 2012
- Orf virus DNA vaccines expressing ORFV 011 and ORFV 059 chimeric protein enhances immunogenicityVirology Journal, 2011
- Current strategies for subunit and genetic viral veterinary vaccine developmentVirus Research, 2011
- Virus-Encoded Homologs of Cellular Interleukin-10 and Their Control of Host Immune FunctionJournal of Virology, 2009
- Delivery Systems for Immunomodulatory Proteins and PeptidesBioDrugs, 1997
- Immune response of lambs to experimental infection with Orf virusVeterinary Immunology and Immunopathology, 1989